Chapel Hill, NCNCT07740941Now EnrollingIRB Ready

Melanoma (Skin Cancer) Clinical Trial in Chapel Hill, NC

Access cutting-edge melanoma (skin cancer) treatment through this phase 2 clinical trial at a research site in Chapel Hill. Study-provided care at no cost to qualified participants.

Sponsored by UNC Lineberger Comprehensive Cancer Center

Quick Self-Assessment

See if you qualify for this Chapel Hill location

Preparing your pre-screening questions…

Expert Care in Chapel Hill

Access melanoma (skin cancer) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related melanoma (skin cancer) treatment provided free

Apply for This Chapel Hill Location

Check if you qualify for this melanoma (skin cancer) clinical trial in Chapel Hill, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chapel Hill

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chapel Hill site if eligible
  4. 4Begin participation

About This Melanoma (Skin Cancer) Study in Chapel Hill

This study evaluates the impact of neoadjuvant Programmed cell death Protein 1 (PD-1)-based treatment regimens in patients with resectable stage IIIB-M1a cutaneous or unknown primary melanoma at high risk of relapse without adjuvant therapy after definitive lymphadenectomy and irrespective of pathologic response outcome on the 2-year overall survival (OS). It was hypothesized that neoadjuvant PD1 inhibitor-based treatment without adjuvant treatment does not significantly (non-inferior) impact OS in this study patient population. Patients will be randomized to either two infusions of pembrolizumab or one infusion of ipilimumab plus nivolumab followed by a single infusion of nivolumab. Patients will undergo follow-up and restaging scans to assess event-free survival at 12 months and OS at 24 months after the first neoadjuvant treatment infusion.

Sponsor: UNC Lineberger Comprehensive Cancer Center

Who Can Participate

Inclusion Criteria

Written informed consent will be obtained to participate in the study, and HIPAA authorization for the release of personal health information.
Subject is willing and able to comply with study procedures based on the judgment of the investigator or protocol designee, including randomization.
Age ≥ 18 years at the time of consent.
ECOG Performance Status of 0-2.
Histological confirmation of cutaneous melanoma or melanoma of unknown primary.
AJCC stage IIIB/IVa resectable disease that is measurable by iRECIST criteria.
Adequate hematologic, renal, hepatic, and heart function

Exclusion Criteria

Prior treatment with PD-1 Programmed cell death Protein 1 (PD-1) and Cytotoxic T-lymphocyte Antigen 4 (CTLA-4).
Has an active autoimmune disease that requires systemic treatment with the use of disease-modifying agents or immunosuppressive drugs. For corticosteroids, up to 10 mg of prednisone daily, or an equivalent dose, is permitted. Hormone replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
Any condition, including laboratory abnormalities, that, in the opinion of the investigator, places the subject at unacceptable risk if he/she were to participate in the study. This includes, but is not limited to, serious medical conditions or psychiatric illnesses that are likely to interfere with participation in this clinical study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chapel Hill?

Yes, this clinical trial (NCT07740941) has an active research site in Chapel Hill, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Melanoma (Skin Cancer) Treatment Options in Chapel Hill, NC

If you're searching for melanoma (skin cancer) treatment options in Chapel Hill, NC, this clinical trial (NCT07740941) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chapel Hill research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced melanoma (skin cancer) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all melanoma (skin cancer) clinical trials near you to find additional studies recruiting in your area.

More Melanoma Trials in Chapel Hill, NC

See all melanoma clinical trials recruiting in Chapel Hill — not just this study.

Browse Melanoma Trials in Chapel Hill →

Browse More Trials by Condition

Melanoma TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Chapel Hill?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chapel Hill, NC